<th id="tlhiz"></th>

<th id="tlhiz"><video id="tlhiz"></video></th>
<big id="tlhiz"></big> <big id="tlhiz"><em id="tlhiz"><track id="tlhiz"></track></em></big>
  1. <center id="tlhiz"><em id="tlhiz"></em></center>
    1. <code id="tlhiz"><nobr id="tlhiz"><track id="tlhiz"></track></nobr></code>

      Recombinant Human Tumor necrosis factor receptor superfamily member 14(TNFRSF14),partial (Active)

      In Stock
      • 貨號:
      • 規格:
      • 圖片:
        • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

        • Measured by its binding ability in a functional ELISA. Immobilized TNFRSF14 at 5 μg/ml can bind human TNFSF14(CSB-MP023991HUj2), the EC50 is 49.85-79.31 ng/ml

          Biological Activity Assay
        • Activity
          Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF14 at 5 μg/ml can bind Biotinylated human TNFSF14 (CSB-MP023991HUj7-B), the EC50 is 1.773-3.707 ng/ml. Biological Activity Assay
      • 其他:


      • 純度:
        Greater than 90% as determined by SDS-PAGE.
      • 內毒素:
        Less than 1.0 EU/ug as determined by LAL method.
      • 生物活性:
        Measured by its binding ability in a functional ELISA. Immobilized TNFRSF14 at 5 μg/ml can bind human TNFSF14(CSB-MP023991HUj2), the EC50 is 49.85-79.31 ng/ml.②Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF14 at 5 μg/ml can bind Biotinylated human TNFSF14 (CSB-MP023991HUj7-B), the EC50 is 1.773-3.707 ng/ml.
      • 基因名:
      • Uniprot No.:
      • 別名:
        HVEML; ATAR; CD270; CD40 like protein precursor; Herpes virus entry mediator A; Herpesvirus entry mediator A; Herpesvirus entry mediator; Herpesvirus entry mediator ligand; HveA; HVEM; HVEM L; LIGHT; LIGHTR; TNFRSF14; TNFSF 14; TNR14_HUMAN; TR2; Tumor necrosis factor receptor like gene2; Tumor necrosis factor receptor superfamily member 14; Tumor necrosis factor receptor superfamily member 14 precursor; Tumor necrosis factor receptor-like 2
      • 種屬:
        Homo sapiens (Human)
      • 蛋白長度:
      • 來源:
        Mammalian cell
      • 分子量:
        48.5 kDa
      • 表達區域:
      • 氨基酸序列
      • 蛋白標簽:
        C-terminal hFc-tagged
      • 產品提供形式:
        Lyophilized powder
        Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
      • 緩沖液:
        If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
        Note: If you have any special requirement for the glycerol content, please remark when you place the order.
        If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
      • 復溶:
        We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
      • 儲存條件:
        Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
      • 保質期:
        The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
        Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
      • 貨期:
        3-7 business days
      • 注意事項:
        Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
      • Datasheet & COA:
        Please contact us to get it.


      • 功能:
        Receptor for BTLA. Receptor for TNFSF14/LIGHT and homotrimeric TNFSF1/lymphotoxin-alpha. Involved in lymphocyte activation. Plays an important role in HSV pathogenesis because it enhanced the entry of several wild-type HSV strains of both serotypes into CHO cells, and mediated HSV entry into activated human T-cells.
      • 基因功能參考文獻:
        1. Data suggest that both HVEM and UL144 bind a common epitope of BTLA, whether engaged in trans or in cis; these studies were conducted in cell lines representing B-lymphocytes, T-lymphocytes, and natural killer cells. (HVEM = human herpes virus entry mediator; UL144 = membrane glycoprotein UL144 of Human herpesvirus 5; BTLA = human B- and T-lymphocyte attenuator) PMID: 29061848
        2. our data suggested that the BTLA/HVEM pathway contributes to peripheral T cell suppression in hepatocellular carcinoma patients PMID: 30116751
        3. TNFRSF14 may serve a tumor suppressive role in bladder cancer by inducing apoptosis and suppressing proliferation, and act as a novel prognostic biomarker for bladder cancer. PMID: 30066919
        4. Primary cutaneous follicle center lymphomas with concomitant 1p36 deletion and TNFRSF14 mutations frequently express high levels of EZH2 protein. PMID: 29858685
        5. High HVEM Expression is Associated with Cancer Progression in Breast Cancer. PMID: 28612127
        6. Report a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. PMID: 26965583
        7. Roles of HVEM are likely to be immunosuppressive rather than activating tumor immunity and it in peripheral blood is a diagnostic marker and therapeutic target for hepatocellular carcinoma. PMID: 27987232
        8. Low HVEM expression is associated with pancreatic and ampullary cancer. PMID: 28470686
        9. HIV-1 produced from CD4+ T cells bears HSV-2 receptor HVEM and can bind to and enter HSV-2-infected epithelial cells depending on HVEM-gD interaction and the presence of gB/gH/gL. PMID: 28809154
        10. Transgenic mice expressing HVEMIg showed a complete resistance to the lethal infection even with 300 MLD50 (survival rate of 100 %). PMID: 28671524
        11. HVEM is highly expressed in ovarian serous adenocarcinoma tissues and correlated with the patient clinicopathological features. PMID: 28365939
        12. TNFRSF14 and MAP2K1 mutations are the most frequent genetic alterations found in pediatric-type follicular lymphoma (PTFL) and occur independently in most cases, suggesting that both mutations might play an important role in PTFL lymphomagenesis. PMID: 28533310
        13. genetic landscape of Pediatric-type follicular lymphoma suggests that TNFRSF14 mutations accompanied by copy-number neutral loss of heterozygosity of the 1p36 locus in over 70% of mutated cases, as additional selection mechanism, might play a key role in the pathogenesis of this disease. PMID: 27257180
        14. The increased immune-stimulatory capacity of lymphoma B cells with TNFRSF14 aberrations had clinical relevance, associating with higher incidence of acute GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation. PMID: 27103745
        15. These results suggest that TNFRSF14 mutations point towards a diagnosis of follicular lymphomas , and can be used in the sometimes difficult distinction between marginal zone lymphomas and follicular lymphomas PMID: 27297871
        16. the overexpression of HVEM in ovarian cancer cells may suppress the proliferation and immune function of T cells, thus leading to the development of ovarian cancer. The current study partially explains the immune escape mechanism of ovarian cancer cells. PMID: 27458100
        17. In eight cases (42%) we observed recurrent copy number loss of chr1:2,352,236-4,574,271, a region containing the candidate tumor suppressor TNFRSF14. PMID: 26650888
        18. Study report the crystal structure of unbound HVEM, which further contributes to the understanding of the molecular mechanisms controlling recognition between HVEM and its ligands. PMID: 26202493
        19. HVEM may play a critical role in tumor progression and immune evasion PMID: 25750286
        20. Data indicate that tumour-expressing herpes virus entry mediator (HVEMplays a critical role in hepatocellular carcinoma (HCC), suggesting targeting HVEM may be a promising therapeutic strategy for HCC. PMID: 25468715
        21. Relative expression of HVEM and LTbetaR modulates canonical NF-kappaB and pro-apoptotic signals stimulated by LIGHT. PMID: 24980868
        22. Sequencing of TNFRSF14 located in the minimal region of loss in 1p36.32 showed nine mutations in pediatric follicular lymphoma. PMID: 23445872
        23. HVEM plays a critical role in both tumor progression and the evasion of host antitumor immune responses, possibly through direct and indirect mechanisms. PMID: 24249528
        24. HVEM gene polymorphisms are associated with sporadic breast cancer in Chinese women. PMID: 23976978
        25. The conformation of the N-terminus of herpes simplex virus gD is induced by direct binding to HVEM and nectin-1. PMID: 24314649
        26. HVEM functions as a regulator of immune function that activates NK cells via CD160 and limits lymphocyte-induced inflammation via association with B and T lymphocyte attenuator PMID: 23761635
        27. BTLA and HVEM may have roles in graft rejection after kidney transplantation PMID: 23375291
        28. Studies indicate co-stimulatory and co-inhibitory receptors B7-1, B7-2, CD28 and TNFRSF14 have a pivotal role in T cell biology, as they determine the functional outcome of T cell receptor (TCR) signalling. PMID: 23470321
        29. These findings support role for BTLA and/or HVEM as potential, novel diagnostic markers of innate immune response/status and as therapeutic targets of sepsis. PMID: 22459947
        30. study described the expression and spatial distribution of HVEM and BTLA in rheumatoid arthritis synovial tissues, and results indicated that HVEM/BTLA may be involved in regulating the progress of joint inflammation PMID: 22179929
        31. HVEM-B and T lymphocyte attenuator (BTLA) interactions impair minor histocompatibility antigen (MiHA)-specific T cell functionality, providing a rationale for interfering with BTLA signaling in post-stem cell transplantation. PMID: 22634623
        32. Results indicate that mHVEM on leukocytes and sHVEM in sera may contribute to the development and/or progression of gastric cancer. PMID: 22113134
        33. These results suggest that the C-terminal portion of the soluble HVEM ectodomain inhibits herpes simplex virus type 1 gD activation and that this effect is neutralized in the full-length form of HVEM in normal infection. PMID: 22239829
        34. TNFRSF14 appears to be a serious candidate gene that might contribute to follicular lymphoma development. PMID: 21941365
        35. HVEM-BTLA cis complex provides intrinsic regulation in T cells serving as an interference mechanism silencing signals coming from the microenvironment. PMID: 21920726
        36. The results of a mutagenesis study of HVEM suggest that the CD160 binding region on HVEM was slightly different from, but overlapped with, the BTLA binding site. PMID: 21959263
        37. data show that HVEM stimulatory signals promote experimental colitis driven by innate or adaptive immune cells PMID: 21533159
        38. Polymorphisms were associated with MS predisposition, with stronger effect in patients with HHV6 active replication-TNFRSF6B-rs4809330(*)A: P=0.028, OR=1.13; TNFRSF14-rs6684865(*)A: overall P=0.0008, OR=1.2. PMID: 20962851
        39. Findings identify TNFRSF14 as a candidate gene associated with a subset of FL, based on frequent occurrence of acquired mutations and their correlation with inferior clinical outcomes. PMID: 20884631
        40. We have identified and replicated a novel gene-gene interaction between 2 polymorphisms of TNFRSF members in Spanish patients with RA, based on the hypothesis of shared pathogenic pathways in complex diseases. PMID: 20187130
        41. Results provide evidence of an existing relationship between HVEM and obesity, which suggest that this TNF superfamily receptor could be involved in the pathogenesis of obesity and inflammation-related activity. PMID: 19680232
        42. Data suggest involvement of TNF superfamily receptor members and ligands in human atherosclerosis. TNFRSF14 (HVEM, TR2, LIGHTR)analysis, found this receptor in regions rich in CD68-positive macrophage-derived foam cells and HLA-DR-positive cells. PMID: 11742858
        43. Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA PMID: 11976496
        44. association of HVEM and nectin-1 with lipid rafts during herpes simplex virus entry PMID: 12915568
        45. sHVEM levels were elevated in sera of patients with allergic asthma, atopic dermatitis and rheumatoid arthritis PMID: 14749527
        46. both nectin 1 and HVEM receptors play a role during HSV infection in vivo and both are highly efficient even at low levels of expression PMID: 15110526
        47. Binding of HVEM to BTLA attenuates T cell activation, identifying HVEM/BTLA as a coinhibitory receptor pair. PMID: 15647361
        48. in cells a complex forms through physical associations of HVEM, HSV-1 gD, and at least gH PMID: 15767456
        49. distinct herpesviruses target the HVEM-BTLA cosignaling pathway, suggesting the importance of this pathway in regulating T cell activation during host defenses. PMID: 16131544
        50. 2.8-A crystal structure of the BTLA-HVEM complex shows that BTLA binds the N-terminal cysteine-rich domain of HVEM and employs a unique binding surface PMID: 16169851



      • 亞細胞定位:
        Membrane, Single-pass type I membrane protein
      • 組織特異性:
        Widely expressed, with the highest expression in lung, spleen and thymus.
      • 數據庫鏈接:

        HGNC: 11912

        OMIM: 602746

        KEGG: hsa:8764

        STRING: 9606.ENSP00000347948

        UniGene: Hs.512898